Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Don't go there

Kosan Biosciences Inc. is betting that cumulative toxicities that halted a Phase II trial of its KOS-862 epothilone analog in colorectal cancer are limited to patients who have previously received oxaliplatin chemotherapy. Oxaliplatin is associated with persistent peripheral neuropathy

Read the full 398 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers